{"id":1304,"date":"2026-09-30T14:00:39","date_gmt":"2026-09-30T18:00:39","guid":{"rendered":"https:\/\/www.celystrapharma.com\/?p=1304"},"modified":"2026-10-08T12:34:56","modified_gmt":"2026-10-08T16:34:56","slug":"health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks","status":"publish","type":"post","link":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/","title":{"rendered":"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Approval marks CELYSTRA Pharma&#8217;s second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Approval marks CELYSTRA Pharma&#8217;s second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_article_pdf_url":"https:\/\/www.newswire.ca\/news-releases\/health-canada-approves-dawnzera-r-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks-867507658.html","_article_pdf_name":"","_page_bg_type":"none","_page_bg_color":"","_page_bg_image_url":"","_page_bg_image_size":"cover","_page_bg_image_position":"center center","_page_bg_image_repeat":"no-repeat","_page_bg_image_fixed":false,"footnotes":""},"categories":[18],"tags":[],"class_list":["post-1304","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks | Celystra Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks | Celystra Pharma\" \/>\n<meta property=\"og:description\" content=\"Approval marks CELYSTRA Pharma&#039;s second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/\" \/>\n<meta property=\"og:site_name\" content=\"Celystra Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T18:00:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-08T16:34:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.celystrapharma.com\/wp-content\/uploads\/2026\/07\/celystra-pharma-FB-social-media-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Annie St-Amant\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Annie St-Amant\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/\"},\"author\":{\"name\":\"Annie St-Amant\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#\\\/schema\\\/person\\\/693617cdae84dc7c280c06cb673e39e9\"},\"headline\":\"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks\",\"datePublished\":\"2026-09-30T18:00:39+00:00\",\"dateModified\":\"2026-10-08T16:34:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/\"},\"wordCount\":38,\"publisher\":{\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#organization\"},\"articleSection\":[\"Press release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/\",\"url\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/\",\"name\":\"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks | Celystra Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#website\"},\"datePublished\":\"2026-09-30T18:00:39+00:00\",\"dateModified\":\"2026-10-08T16:34:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/\",\"name\":\"Celystra Pharma\",\"description\":\"Illuminating life at the cellular level\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#organization\",\"name\":\"Celystra Pharma\",\"url\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.celystrapharma.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/logo-celystrapharma-horizontal.svg\",\"contentUrl\":\"https:\\\/\\\/www.celystrapharma.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/logo-celystrapharma-horizontal.svg\",\"width\":290,\"height\":46,\"caption\":\"Celystra Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/celystrapharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.celystrapharma.com\\\/en\\\/#\\\/schema\\\/person\\\/693617cdae84dc7c280c06cb673e39e9\",\"name\":\"Annie St-Amant\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks | Celystra Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/","og_locale":"en_US","og_type":"article","og_title":"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks | Celystra Pharma","og_description":"Approval marks CELYSTRA Pharma's second product approved by Health Canada in nine months and brings a new treatment option for Canadians living with hereditary angioedema.","og_url":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/","og_site_name":"Celystra Pharma","article_published_time":"2026-09-30T18:00:39+00:00","article_modified_time":"2026-10-08T16:34:56+00:00","og_image":[{"width":2560,"height":1600,"url":"https:\/\/www.celystrapharma.com\/wp-content\/uploads\/2026\/07\/celystra-pharma-FB-social-media-1.jpg","type":"image\/jpeg"}],"author":"Annie St-Amant","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Annie St-Amant","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/#article","isPartOf":{"@id":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/"},"author":{"name":"Annie St-Amant","@id":"https:\/\/www.celystrapharma.com\/en\/#\/schema\/person\/693617cdae84dc7c280c06cb673e39e9"},"headline":"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks","datePublished":"2026-09-30T18:00:39+00:00","dateModified":"2026-10-08T16:34:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/"},"wordCount":38,"publisher":{"@id":"https:\/\/www.celystrapharma.com\/en\/#organization"},"articleSection":["Press release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/","url":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/","name":"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks | Celystra Pharma","isPartOf":{"@id":"https:\/\/www.celystrapharma.com\/en\/#website"},"datePublished":"2026-09-30T18:00:39+00:00","dateModified":"2026-10-08T16:34:56+00:00","breadcrumb":{"@id":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.celystrapharma.com\/en\/health-canada-approves-dawnzera-donidalorsen-for-the-prevention-of-hereditary-angioedema-attacks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.celystrapharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Health Canada Approves DAWNZERA\u00ae (donidalorsen) for the Prevention of Hereditary Angioedema Attacks"}]},{"@type":"WebSite","@id":"https:\/\/www.celystrapharma.com\/en\/#website","url":"https:\/\/www.celystrapharma.com\/en\/","name":"Celystra Pharma","description":"Illuminating life at the cellular level","publisher":{"@id":"https:\/\/www.celystrapharma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.celystrapharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.celystrapharma.com\/en\/#organization","name":"Celystra Pharma","url":"https:\/\/www.celystrapharma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.celystrapharma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.celystrapharma.com\/wp-content\/uploads\/2026\/06\/logo-celystrapharma-horizontal.svg","contentUrl":"https:\/\/www.celystrapharma.com\/wp-content\/uploads\/2026\/06\/logo-celystrapharma-horizontal.svg","width":290,"height":46,"caption":"Celystra Pharma"},"image":{"@id":"https:\/\/www.celystrapharma.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/celystrapharma\/"]},{"@type":"Person","@id":"https:\/\/www.celystrapharma.com\/en\/#\/schema\/person\/693617cdae84dc7c280c06cb673e39e9","name":"Annie St-Amant"}]}},"_links":{"self":[{"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/posts\/1304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/comments?post=1304"}],"version-history":[{"count":2,"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/posts\/1304\/revisions"}],"predecessor-version":[{"id":1439,"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/posts\/1304\/revisions\/1439"}],"wp:attachment":[{"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/media?parent=1304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/categories?post=1304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.celystrapharma.com\/en\/wp-json\/wp\/v2\/tags?post=1304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}